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INTRODUCTION 
 
 High blood pressure is considered to be the third most important 
risk factor for non- communicable Southern Asia (2010)(1). Hypertension 
causes a considerable public health burden on the cardiovascular health 
status of individuals and also on the healthcare providers in India.(2) It is 
considered to be directly responsible for 58% of all stroke deaths and 
23% of coronary heart disease (CHD) related deaths in India.(3) The 
World Health Organization rates Hypertension as one of the most 
important risf factors for premature deaths in the world. A systematic 
analysis of population health data for attributable deaths and attributable 
disease burden done by  The Global and Regional Burden of Disease and 
Risk Factors study has ranked Hypertension in Southern Asia as the 
second important factornext only to child underweight for age. (4) About 
34% urban and 24% rural Indians are hypertensive. Among which, only 
25% of the rural and 42% of the urban Indians are aware of their 
hypertensive status. Of this only 25% of the rural and 38% of urban 
Indians are being treated for hypertension.(5) 
 
 Hypertension causes end-organ damage including hypertensive 
retinopathy.(6) Current studies have indicated that the effects of systemic 
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hypertension on the retinal, optic nerve head and choroidal circulation 
produce three distinct and independent manifestations:  
(i) hypertensive choroidopathy, (ii) hypertensive optic neuropathy, and 
(iii) hypertensive retinopathy.(7,8)However the classification techniques 
for grading hypertensive retinopathy currently in practice,are shown to 
have poor correlation with the degree of severity of hypertension. Large 
population based studies have shown that the fundus lesions described in 
hypertensive individuals can also occur in normal elderly indiviuals.(9–
11) Poorly controlled systemic hypertension has been shown to be one of 
the most important comorbid factors in the worsening of microvascular 
disease of the eye like diabetic retinopathy.(12)Though the exact 
relationship has not yet been fully understood. Systemic hypertension is 
considered to be one be the contributing factors for several ocular 
diseases. Choroidal lesions secondary to elevated blood pressure are less 
well recognized than retinopathy in the current literature. 
 
 The choroid formsthe posteriorpart  of  the  uveal tissue,  the  
middle  layer  of  the  eye.  The primary function of the choroid is to 
provide oxygen and nutrients to the retina.  With the advent of Enhanced 
depth-imaging optical imaging  ([EDI-OCT] ;  as  defined  by  Spaide  et  
al.(13) )  in-vivo  imaging  of  the     choroid  has  now  become  possible.  
The smooth muscle of  the  vessel  walls  of  the  choroid  are  innervated  
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by  both the sympathetic and parasympathetic system,  which  form dense 
plexuses of fibers around the vessels (“perivascular plexus”). The choroid 
vasculature is principally under neurogenic control. In contrast to the 
retinal vasculature, the choroid does not exhibit any auto regulation. 
(14)Pterygopalatine ganglion provides the parasympathetic supply to the 
choroid.(15)They are mainly cholinergic fibers abundant in 
parasympathetic vasodilatory mediators like the vasoactive intestinal 
peptide and nitric oxide.(16) The sympathetic fibres are mainly 
noradrenergic fibres mediating vasoconstriction and are supplied 
primarily by the ciliary ganglion.(17) 
 
 In the past, many lesions attributable to hypertensive 
choroidopathy have been erroneously classified as being caused by 
hypertensive retinopathy. Hypertensive choroidopathy has been 
associated with toxemia of pregnancy, pheochromocytoma, renal 
disorders, and malignant hypertension.(18)Hayreh defined lesions 
attributable to hypertensive choroidopathy as initial, acute, and chronic, 
based on studies in rhesus monkeys. (19),(20) The circulatory levels of 
several endogenous vasoconstrictive mediators has been shown to 
increase in patients with malignant hypertension. These substances 
include potent vasoconstrictors such as adrenaline, angiotensin II, 
adrenaline, vasopressin, and endothelin-1 (ET-1). Such substances can 
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easily pass from the fenestrated choriocapillaris to the interstitial area of 
the choroid, causing severe vasoconstriction and tissue ischemia in the 
choriocapillaris. Thus, the choroidal lesions (Elschings spots and 
Siegrist’s streaks) of malignant hypertension develop. Similar changes 
has been shown to occur in the blood and sympathetic system in patients 
with chronic essential hypertension.(21) 
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STRUCTURE AND FUNCTION OF THE 
CHOROID 
EMBRYOLOGY OF THE CHOROID: 
 The choroid develops from two types of embryonic tissues: the 
cranial neural crest cells and the mesoderm. 
The choroid is considered to develop in three stages: 
i. First and second months:  development of capillaries 
ii. Third month: development of veins 
iii. Fourth month: development of arteries.(22) 
 The choroidal melanocytes and the stroma are considered to 
develop both from the mesoderm and the neural crest cells. (23–25) 
 
ANATOMY OF THE CHOROID: 
The choroid is the posterior part of the uveal tissue, the middle 
covering of the eye (Fig 1). The choroid measures 0.23 to 0.30 mm in 
thickness in the posterior pole of the eye and 0.11 to 0.15 mm anteriorly 
and peripherally. This variation in diameter is due to the greater 
concentration of choroidal arteries and large-and medium-sized choroidal 
veins in the posterior choroid. The choroid can be further subdivided into 
three parts from internal to external: (1) Bruch's membrane; (2) Layers of 
choroidal vasculature ; and (3) the suprachoroid.
 
 
 
 
 
 
 
FIG 1: PHOTOMICROGRAPH OF THE THREE LAYERS AT 
THE BACK OF THE PRIMATE EYE.
  
HISTOLOGY OF THE CHOROID:
Histologically, the choroid is most commonly described as five layers:
1. Bruch’s membrane
2. Choroiocapillaries
3. Medium-sized vessels (Haller’s layer)
4. Large-sized vessels (Sattler’s layer)
5. Suprachoroid(Fig 2).
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(26) 
 
 FIG 2:LAYERS OF CHOROIDAL VASCULATURE A: 
HISTOLOGICAL SECTION (H/E). B: THREE
SCHEME  
1: Sclera; 2: Suprachoroid; 3: Haller´s Layer; 4: Medium
layer Sattler´s Layer ; 5Choriocapillaries; 6: Bruch´s membrane; 7: 
Retinal pigment epithelium
SUPRACHOROID  
 The suprachoroid forms the outer layer of the choroid.It is a 
transition zone between the innermost part of the sclera and the layer of 
medium-sized vessels (Haller’s layer). It is formed bycollagen fibres, 
14 
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fibroblasts, melanocytes, elastic fibres, nerve plexus, smooth-muscle 
cells, and intrinsic choroidal neurons (ICNs).(27–31) 
 
CHOROIDAL VASCULATURE AND STROMA: 
 The choroid is a highly vascular structure. Most of the choroid is 
made up of blood vessels that gradually decrease in size from outer to 
inner as the vessels branch. It is composed of arteries, veins, arterioles, 
capillariesand a vascular stroma.The choroidal stroma contains collagen 
and elastic fibres, non-vascular smooth cells, numerous melanocytes, 
fibroblasts, mast cells, macrophages, and lymphocytes. The arterial 
vessels of the choroid are branches of the posterior ciliary arteries (PCAs) 
.It also receive blood supply from some recurring branches of the major 
arterial circle of the iris. The vessels become smaller in diameter in a 
branching hierarchy towards the capillary bed. This enables the 
identification of the three vessel layers of decreasing caliber: a inner layer 
of interconnected capillaries (the choriocapillaris), an intermediate layer 
of medium-sized vessels (Sattler’s layer), and an outer layer of large-
sized vessels (Haller’s layer) outer layer of large-sized vessels (Haller’s 
layer)(32) 
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BRUCH’S MEMBRANE 
 Bruch’s membrane forms the innermost layer of the choroid. It is 
an acellular structure. According to electron microscopic studies, the 
Bruch’s membrane can be divided into five layers, which, from the retinal 
side towards the choroid are:  
1.The basal membrane of the Retinal Pigment Epithelium. 
2. The inner collagen layer,  
3. The elastic-fibre layer,  
4. The outer collagen layer, and  
5.The basement membrane of the choriocapillaries.(33,34)  
 
INNERVATION OF THE CHOROID: 
 The choroidal innervation is largely made up ofnervefibre bundles 
from both the autonomic nervous system and the central nervous system 
(Fig 3 ). The sympathetic fibres are from the superior cervical ganglion. 
The parasympatheticfibres arise from the pterygopalatineand ciliary 
ganglion. These nerve fibres reach the choroid in three directions:i) 
around the Short Posterior cilairy artery, these fibres arise from the 
plexuses around the internal carotid and continue along with the 
ophthalmic artery until reaching the SPCA in the choroid; ii) through the 
short posterior ciliary nerves that are derived from the from the ciliary 
ganglion; or iii) through the long posterior ciliary nerves that come from 
the nasociliary nerve .In addition to these nerve fibres, the
alsohas intrinsic choroidal neurons. 
  
 
 
 
 
 
 
 
 
  
FIG 3: DEPICTING THE 
CHOROIDAL VASCULATURE
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(31,35) 
AUTONOMIC CONTROL OF 
. 
 
choroid 
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FUNCTIONS OF THE CHOROID  
 Nutrient and oxygen supply to the outer retina especially the 
photoreceptors. 
 Thermoregulation by the dissipationof heat 
 Maintenance of intraocular pressure 
 Drainage of aqueous humor 
 Absorption of scattered light 
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CHOROIDAL HEMODYNAMICS 
CHOROIDAL BLOOD SUPPLY:  
 The choroid receives its arterial blood from THE branches of 
the ophthalmic artery. The nasal and temporal short posterior ciliary 
arteries and the nasal and temporal long posterior ciliary arteries are 
branches of the posterior ciliaryartery which is a branch of the ophthalmic 
artery. All anterior ciliary arteries are all direct branches from the 
ophthalmic artery, except for the one anterior ciliary artery accompanying 
the lateral rectus. This anterior ciliary artery is derived from the 
ophthalmic artery as a branch of the lacrimal artery .Although the retinal 
vessels also arise from the ophthalmic artery, the retinal and choroidal 
blood supplies are distinct and seperate within the eye and there is little, 
if any, anastomosis between the two systems (Fig 4 ). 
 
 
 
 
  
FIG4. THE BLOOD SUPPLY OF THE CHOROID
 1.ophthalmic Artery 2.Central retinal artery 3.ciliary arteries 
4.Long posterior ciliary artery 5.short posterior ciliary artery 
6.Suprachoroidal space 7.Posterior ethmoidal arteries 8. Anterior 
ethmoidal arteries  
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CHOROIDAL BLOOD FLOW: NOURISHMENT OF THE 
RETINA 
 In spite of the conspicuous retinal blood vessels, the major blood 
supply to the retina is the choroidal vasculature.The photoreceptors 
consume more than 90-92% of the oxygen .The photoreceptors are one of 
the most metabolically active cells in the body. This is important 
especially in darkness when active ion transport is necessary to maintain 
ion homeostasis and to keep the ligand-gated channels open. In darkness, 
choroidal circulation provides 90% of the oxygen.(36) Due to presence of 
barriers like the Bruch’s membrane and the RPE, a steep oxygen tension 
gradient is necessary. This is possible because of the high blood flow in 
the choroid, possibly the highest in the body per unit tissue 
weight.(37)Therefore, the arterial/venous gradient in the choroid is only 
3% compared to the retinal circulation where the gradient is around 40%. 
In several species, the choroidal arteries supplies both the inner retina and 
the outer retina as the retinal blood vessels are sparse (e.g., rabbit) or 
absent (e.g., guinea pig ) . In guinea pigs, oxygen tension shows a rapid 
decline, to almost 0 mm Hg, within approximately 70 μm of Bruch's 
membrane and so the inner retina functions in an anoxic environment 
which is possible only by anaerobicmetabolism. In contrast, in other 
vascular retinas the inner retinal oxygen tension is around 20mm 
maintained by the retinal vessels. (38,39) In the retina, the capillaries are 
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without fenestrationsforming the blood-ocular barrier, and so are 
impermeable to even small molecular weight molecules. Thus the role of 
choroidal circulation is highly crucial in supplying oxygen as well as 
nutrients because the capillaries of the choroid are fenestrated. These 
fenestrations have a high permeability not only to glucose but also to 
several low molecular weight substances such as albumin. 
 
REGULATION OF CHOROIDAL BLOOD FLOW: 
 The smooth muscle of the vessel walls  of  the  choroid  are  
innervated  by  both the sympathetic and parasympathetic system,  which  
form dense plexuses of fibers around the vessels (“perivascular plexus”). 
The choroid vasculature is principally under neurogenic control. In 
contrast to the retinal vasculature, the choroid does not exhibit any 
autoregulation. (14)Pterygopalatine ganglion provides the 
parasympathetic supply to the choroid.(15)They are mainly cholinergic 
fibres abundant in parasympathetic vasodilatory mediators like the 
vasoactive intestinal peptide and nitric oxide.(16) The sympathetic fibres 
are mainly noradrenergic fibres mediating vasoconstriction and are 
supplied primarily by the ciliary ganglion.(17) 
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CHOROIDAL HEMODYNAMICS IN EYE DISEASES: 
 Choroidal circulation has been found to be significantly slower in 
patients with normal tension glaucoma, proliferative diabetic retinopathy 
and age-related macular degeneration.(40–42) 
 
CHOROIDAL WATER SHED ZONES: 
 The border between the areas of distribution of any two end- 
arteries in a tissue is called a ‘ water-shed’ zone. All choroidal arteries are 
end arteries. 
The choroidal vasculature has several such watershed zones, which 
are arranged as follows: 
 Between Posterior ciliary arteries (PCA) (Fig 5) 
 Between short PCA 
 Between the short and long PCAs 
 Between the PCAs and the anterior ciliary arteries 
 Between the choriocapillaris lobules 
 Between the vortex veins 
 
 
 
 
 
FIG 5. FIGURE DEPICTING THE PRESENCE OF WATERSHED 
ZONES IN THE CHOROIDAL 
MEDIAL AND LATERAL POSTERIOR CILIARY ARTERIES.
 
    The close proximity of the choroidal watershed zones to the 
peripapillary region and the macula may prove the possible role of 
choroidal blood flow in ischemic optic neuropathies 
ischemic lesions. 
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VASCULAR BED BETWEEN THE 
and in macular 
 
PERIPAPILLARY CHOROIDAL BLOOD FLOW:
 The peripapillary choroid has been reported to play a vital role in 
the pathophysiology of several ocular diseases including pathological 
myopia and glaucoma. Peripapillary choroidal
major part of the blood supply to the laminar and prelaminar regions of 
the optic nerve head. 
  
FIG. 6:  DIAGRAMMATIC REPRESENTATION OF BLOOD 
SUPPLY OF OPTIC NERVE HEAD
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 blood vessels provide 
 
 
 
ESSENTIAL HYPERTENSION
 
DEFINITIONAND CLASSIFICATION OF 
PRESSURE (JNC 7): 
 According to the Seventh report of the Joint National Committee 
on the Prevention, Detection, Evaluation and treatment of high blood 
pressure, Hypertension is defined as 
 
 
 
 
 
 
 
 “The diagnosis of hypertension is made when 
more diastolic BP measurements on at least 2 subsequent visits is 
consistently greater than or equal to 90 mm Hg or when the average of 
multiple systolic BP readings on 2 or more subsequent visits is 
consistently greater than or equal
hypertension is defined as systolic BP greater than or equal to140 mm Hg 
and diastolic BP less than 90 mm Hg.”
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HIGH BLOOD 
 
the average of two or 
 to140 mm Hg. Isolated systolic 
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DEFINTION OF ESSENTIAL HYPERTENSION: 
 Essential, idiopathic, or primary hypertension is defined as “ high 
blood pressure in which secondary causes such as renovascular disease, 
renal failure, pheochromocytoma, hyperaldosteronism, or other causes of 
secondary hypertension or Mendelian forms are not present ”. 
 
PATHOGENESIS AND PATHOPHYSIOLOGY: 
The pathogenesis of essential hypertension is a complex interplay 
between  
1. Genetic predisposition 
2. Lifestyle and environmental influences and  
3. Disturbances in vascular structure and neurohumoral control 
mechanisms (Fig 7). 
PATHOPHYSIOLOGY:  
  Acharacteristic feature ofprimary hypertension is an inappropriate 
increase in the peripheral vascular resistance of the medium-sized vessels 
relative to the cardiac output. This happens because of the mechanical 
remodelling of the arterioles, which is characterized by an increase in 
their media/lumen ratio. However, this is now considered to be a 
consequence rather than the cause for essential hypertension.Endothelial 
dysfunction is seen in essential hypertension along with decreased 
production of nitrous oxide. However the above-mentioned features are 
more likely to be a consequence rather than the cause for increased blood 
pressure. Though the specific role of the renin
etiopathogenesis of hypertension is largely unclear, therapeutic agents 
acting on this system have shown good control of blood pressure. Though 
the blood pressure and the vascular tone is controlled by the sympathetic 
nervous system, its role in the maintenance of chronic hypertension is 
unclear. 
 
FIG 7: PATHOGENESIS OF ESSENTI
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AL HYPERTENSION. 
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HYPERTENSION AND END-ORGAN DAMAGE: 
Hypertension damages blood vessels and thus causes damage to 
end-organs. The mechanisms causing this injury are complicated and, 
although studied for years in experimental animal models, are only 
hypothetical. The endothelial layer acts as an interface for signal 
transduction for the hemodynamic forces, which play a role in the 
regulation of vascular tone and in the chronic arterial structure 
remodelling. Effects of these hemodynamic mechanical forces on gene 
expression and signal transduction in endothelial cells have been 
demonstrated.(43) Mechanical stress initiates several pathways including 
integrin interaction of cells and matrix, tyrosine kinase activation, ion 
transfer,autocrine production, and growth factor release .(44) Increased 
blood flow through small arteries has been reported to increase the 
production of connective tissue and promote tunica media hypertrophy, 
mostly through the proliferation of thesmooth muscle cells. Increased 
pressure is capable of the process of induction of early response genes in 
thewall of the arteries. Increased Oxyradical production by endothelial 
cells, seen in hypertensive mammals due to xanthine oxidase, results in 
leukocyte-endothelial adhesion that in turnresults inthe surface expression 
of different cell adhesion molecules.(45)Leukocyte infiltration of the 
endothelium resulting in the setting up of the inflammatory cascade 
including the release of chemokines. 
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 Mechanical forces alone are capable of initiating events resulting 
in remodeling of the vessels and subsequent end-organ damage. But, 
hypertension is not merely a process of mechanical events. All forms of 
hypertension involve mediators, which are independent of the arterial 
pressure. 
 
VASOCONSTRICTIVE MEDIATORS IN ESSENTIAL 
HYPERTENSION: 
The circulatory levels of several endogenous vasoconstrictive 
mediators have been shown to increase in patients with malignant 
hypertension. These substances include potent vasoconstrictors such as 
adrenaline, angiotensin II, adrenaline, vasopressin, and endothelin-1 
(ET-1). Since the choriocapillaris are fenestrated, such molecules can 
cause vasoconstriction of the vessels.    
 
EFFECT OF HYPERTENSION ON CHOROIDAL VESSELS: 
The choroid is one of the most vascular tissues in the body. It is 
affected by changes in intraocular pressure, endogenous nitric oxide, 
vasoactive substances produced by the choroidal ganglion cells and 
circulating catecholamines. Studies have shown the absence of 
autoregulation in choroidal vasculature in contrast to the retinal vessels. 
A reduction in choroidal blood flow stimulates the activation of the 
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sympathetic nervous system and release of noradrenaline. Noradrenaline 
promotes vasoconstriction by its action on the alpha-1 receptors. The 
choroidal is capable of some autoregulation by manipulating the mean 
arterial pressure and IOP as reported by Riva et al who showed a increase 
of only 12% of choroidal blood flow with a 60% increase in ocular 
perfusion pressure. 
The choroid is the major source of oxygen and nutrients to the 
outer retina. Thus, even a small change in the perfusion pressure of the 
choroid may impair the functioning of the retina. The increased levels of 
circulating vasoactive substances are now considered to be behind the 
pathogenesis of hypertensive choroidopathy in malignant hypertension. 
The circulatory levels of several endogenous vasoconstrictive mediators 
have been shown to increase in patients with malignant hypertension. 
These substances include potent vasoconstrictors such as adrenaline, 
angiotensin II, adrenaline, vasopressin, and endothelin-1 (ET-1). Since 
the choriocapillaris are fenestrated, such molecules can cause 
vasoconstriction of the vessels.    
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OCULAR MANIFESTATIONS OF 
HYPERTENSION 
 Systemic hypertension by its effect on the blood vessels of the 
choroid and the retina produces three characteristic manifestations in the 
eye 
i. Hypertensivechoroidopathy 
ii. Hypertensive optic neuropathy and  
iii. Hypertensiveretinopathy 
 
HYPERTENSIVE RETINOPATHY: 
 Hypertensive retinopathy was first described by Liebreich in 
1859.(46) It represents the end-organ damage in patients with elevated 
systemic arterial blood pressure. 
 
CLINICAL FEATURES: 
 The fundus features commonly described in hypertensive 
retinopathy include microaneurysms, generalized arteriolar narrowing, 
cotton-wool spots, intra-retinal hemorrhages, hard exudates and optic disc 
swelling. Changes of secondary arteriolosclerosis are, changes in the 
arteriolar light reflex and periarteriolar vessel sheathing, arteriovenous 
crossing changes and vasoconstriction.(47) 
  
Table 1. The Keith, Wagener, and Barker hypertensive retinopathy 
classification (Grade I-IV), based on the level of severity of the retinal 
findings 
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HYPERTENSIVE CHOROIDOPATHY
 Hypertensive choroidopathyusually occurs in young adults who 
experience an acute episode of hypertension associated usually with 
preeclampsia, pheochromocytoma, or renal hypertension.
 
CLINICAL MANIFESTATIONS:
 Lobular nonperfusion of the choriocapillaris results in 
pigmented patch surrounded by a margin of hypopigmentation known 
as Elschnig spots(Fig 8). 
 
FIG 8. RED-FREE FUNDUS PHOTOGRAPH SHOWING 
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ELSCHNIG SPOTS. 
ahyper 
 Siegrist streaks are linearhyper pigmented configurations 
thatusually follow the meridional 
with malignant hypertension (Fig 9)
focal choroidal hypoperfusion in the early phases and multiple areas of 
subretinal fluid leakage in late phases. Though focal detachments of the 
retinal pigment epithelium may be seen exudative retinal detachments are 
extremely rare. The more commonly described features of hypertensive 
choroidopathy are choroidal vascular sclerosis, Elschnig spots and 
Siegrist's streaks. 
 
 
FIG 9. FUNDUS PHOTOGRAPH S
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course of choroidal arteries in patients 
.Fluorescein angiography reveals 
HOWING SIEGREST STREAK 
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PATHOGENESIS: 
 
 
 
 
 
 
 
Marked elevation of systemic BP
Autonomic regulatory capacity exceeded
Fibrin-platelet obstruction
Obstruction of choroida choriocapillaries
Necrosis of overlying RPE
Fibrinous exudation
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 OPTICAL COHERENCE TOMOGRAPHY 
 Optical coherence tomography (OCT) was first demonstrated for 
cross sectional retinal imaging in 1991 by a Massachusetts Institute of 
Technology team lead by Fujimoto.(48) Since its inception, it has become 
a clinically useful diagnostic toolin ophthalmology.  
 
EVOLUTION OF OCT: 
 At its inception, time-domain OCT was the technique employed by 
commercially available OCT systems like the Stratus OCT. Time-domain 
OCT (TD-OCT) systems which featured an axial resolution of 8–10 μm 
in tissue with scan rates of 400 A-scans per second with.(49) The first 
commercially available spectral-domain (Fourier domain) OCT (SD-
OCT) system was introduced in 2006. Spectral Domain OCT works on 
the principle of detection of the light echoes simultaneously by measuring 
the interference spectrum of the reflected light, using a high-speed 
spectrometer and an interferometer. This technique a resolution of 5–7 
μm in tissue and scan rates of 20000 – 50000 A- scans per second. 
 Although OCT has been used extensively for in the diagnosis and 
prognosticating of many posterior segment diseases based on macular, 
optic nerve and RNFL images, until recently, the choroid was not able to 
be clearly imaged with the spectral domain OCT. 
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 The poor visibility of the choroid in Stratus OCT is due to the 
presence of the hyperpigmented Retinal pigment epithelium which causes 
high light scattering resulting in the attenuation of the relatively weak 
choroidal reflection signal. Also, the relatively low signal to noise ratio of 
time domain OCT does not help in producing high quality images of 
deeper structures like the choroid. Due to the limited number of A-scans 
possible in time domain OCT the pixel quality is limited making 
visualization of the choroid difficult. 
 Techniques such as image averaging and enhanced depth imaging 
(EDI) has enabled SD-OCT systems to image the choroid. Image 
averaging involves increasing the signal-to-noise ratio by procuring 
multiple B-scans from the same location that are averaged 
together.(13,50) When multiple images are averaged, the software 
reduces the 'speckle.' This improves the image quality [Fig. 10]. Along 
with image averaging, Enhanced Depth Imaging involves setting the 
choroid adjacent to the zero delay line. This allows enhanced 
visualization of the choroid up to the sclera [Fig 11]. (13,51–53)  
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
FIG 10: Optical coherence tomography (OCT) images obtained using 
Cirrus high definition OCT (HD
improving imaging quality with increased B
averaging. a) single B 
averaged showing the chorioscleral interface.
 Apart from the already available commercially systems, newer 
prototype OCT systems have now started to emerge contributing greatly 
to this ever growing field .Some examples of such prototype OCT 
systems are ultra high-resolution
39 
-OCT) system showing the 
-scan and image 
–Scan. b) 5 B-scans averaged c) 20 B
 
 OCT (UHR-OCT), SD-OCT systems 
-scans 
employing a longer-wavelength light source permitting deeper tissue 
penetration, and swept-source OCT (SS
 
FIG 11: (a) Cirrus OCT WITHOUT EDI ; (b) OCT WITH EDI ;
(c) Swept-Source OCT ; Red arrow heads indicate the             
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-OCT) systems.(54)  
chorioscleral interface. 
               
PRINCIPLES OF OPTICAL COHERENCE TOMOGRAPHY:
  Optical coherence tomography is based on the 
light interferometry and highly sensitive to even minute changes in the 
refractive index of the sample. Therefore this feature helps to deliver 
additional information to other imaging modalities like computed 
tomography (CT) and magnetic
is depicted in figure 12.Interferometry is used to compare the reflected 
wave from different depths of the tissue to the reference wave. The 
detected signal contains information on the position of the scatters withi
the sample, on their reflectivity, velocity and polarization properties.By 
this collection of depth scans from the sample three dimensional 
construction of cross-sectional images is possible.
FIG 12: PRINCIPLE OF OCT: GEOMETRICAL INFORMATION 
IS GAINED BY PARTLY REFLECTED INFRARED LIGHT 
FROM VARIOUS DEPTHS WITHIN THE SAMPLE.
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principle of white 
 resonance imaging (MRI). This principle 
 
 
n 
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OCT SYSTEM DESIGNS: 
Optical coherence tomography system designs. 
A. Time domain OCT system: This system is based on the principle of 
longitudinal translation of the reference arm pathlength in time. 
The depth (axial) of the scan is obtained by moving the reference 
mirror towards and away from the beam splitter. The beam splitter 
directs the broadband light source into two beams. One beam is 
directed toward the reference mirror while the other beam is 
directed towards the sample. The beam splitter then combines the 
reflected signals from both the reference mirror and the sample and 
directs them to the detector. The sweep distance of the reference 
arm mirror gives the axial scan. 2D scan is obtained by making the 
sample bean move in a linear manner and a 3D scan by moving in 
a complex surface array.  
B. Spectrally encoded Fourier domain OCT system: The reference 
arm is placed at a fixed distance. Similar to the Time-Domain 
OCT, the beam splitter directs the beam to the reference mirror and 
sample and redirects the reflected signals to the detector. This 
beam is then directed to spectrophotometer which encodes 
spectrally the interference signal to provide reflectance 
information.  
C. Swept source OCT system: the source laser rapidly sweeps across 
the spectral frequency band. As the reflected signals from the 
sample and fixed reference 
and directed towards the detector, an axial scan is constructed from 
the depth resolved spectral interference signals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 13: OCT DESIGN SYSTEMS
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arm are combined at the beam splitter 
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APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY: 
 To analyze morphological changes and to quantify progression in 
various disease states. For example, to monitor the progress of diseases 
such as wet age-related macular degeneration by measuring the retinal 
thickness. Measuring the macular edema in retinal diseases like diabetic 
retinopathy and vein occlusions. Differentiating and classifying macular 
holes. Evaluation of the vitreoretinal surface. To measure the retinal 
nerve fibre layer thickness to help monitor nerve fibrelayer damage in 
glaucoma. It also helps in the studying the morphology of the optic nerve 
head. 
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CHOROIDAL IMAGING 
 The choroid until recently has been a little understood anatomical 
structure due to its presence behind the retinal pigment epithelium. Now 
with the advent of the newer OCT systems such as Enhanced Depth 
Imaging, imaging of the choroid is now possible enabling better 
understanding regarding the etiology and pathogenesis of several retinal 
diseases. 
DEVELOPMENT OF EDI: 
 Enhanced Depth Imaging was pioneered in 2009 by 
ophthalmologists Richard Spaide, MD and Ron Margilis, MD.(55) Before 
this, imaging of the choroid was almost impossible .The factors 
responsible for this invisibility of the choroid are 
 Limited axial length 
 Light scatter by choroidal vasculature 
 Heavily pigmented retinal pigmented epithelium 
 Motion artifacts 
 However with the advent of the EDI technology by simply 
positioning the patient slightly closer to the machine imaging of the 
choroid is possible. This is done by inverting the image which brings the 
choroid/sclera interface closer to the zero delay line. This zero delay line 
by convention is present at the top of the imaging scree and it represents 
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the area of the most precise focus.3 EDI-OCT provides an additional 500 
– 800 micron tissue penetration compared to the conventional OCT.6  
 Some of the commercially available EDI-OCT models are Cirrus 
HD-OCT, Spectralis and RTVue. 
 
OTHER CHOROIDAL IMAGING MODALITIES:. 
 The newest OCT system to be commercially available is the 
Swept-Source OCT system( SS-OCT) .This provides the following 
advantages over the Spectralis OCT 
 Longer wavelength source (1050nm ) 
 Frequency-swept light source 
 The longer wavelength source enable deeper penetration of 
tissue.Also the presence of photodiodes compared to the spectrometer in 
conventional OCT systems helps in more efficient detection of 
interference patterns. The axial resolution of the SS-OCT is around 
5.3µm with an acquisition speed of 100,000 to 400,000 A-scans per 
second. 
 
 
 
 
 
CHOROIDAL THICKNESS
CHOROIDAL THICKNESS MEASUREMENTS:
The choroidal thickness is manually measured by drawing a 
perpendicular line from the outer edge of the retinal 
to the chorio-scleral junction.Several studies have shown that the 
choroidal thickness measured in normal individuals is highly 
reproducible.(50,56) Shao et al. reported “ very high reproducibility with 
a mean difference of 3.14 ± 13.1 lm between the observers 
”.(57)SimilarlyChabblani et al rep
automated segmentation of retinal layers.
 
FIG 14: SPECTRALIS HD
THICKNESS FROM THE HYPERREFLECTIVE RPE TO THE 
CHORIO
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pigment epithelium 
orted high reproducibility using the 
(58) 
-OCT DEPICTING THE CHOROIDAL 
-SCLERAL INTERFACE. 
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CHOROIDAL IMAGING IN NORMAL INDIVIUALS: 
 Subfoveal choroidal thickness in one study was reported to be in 
the normal range from 191 ± 75.2 to 354 ± 112 microns. However this is 
racial variations have been reported .The choroid is thickest in the 
subfoveal region with nasal and inferior choroid being thinner than the 
temporal and superior choroid respectively.(59) 
 
FACTORS AFFECTING CHOROIDAL THICKNESS: 
A. AGE: 
Age is one of the established factors affecting choroidal thickness. 
Margolis et al and Ikuno et al reported a decrease of 15.6 micron 
and 14 microns for every decade respectively.(60,61) 
 
B. AXIAL LENGTH: 
Choridal thickness in inversely proportional to axial length. 
 
C. REFRACTIVE ERROR: 
            Wei et al. reported that the “ subfoveal thickness decreases by 15 
microns for every increase in myopic refractive error of 1 D, or by 32 
microns for every increase in axial length of 1mm”. Fujiwara et al. 
reported“ choroidal thickness decreases by 12.7 lm for each decade of life 
and by 8.7 lm for each diopter of increasing myopia”. 
 D. DIURNAL VARIATION:
 Choroidal thickness is significantly 
 
E ETHINICITY: 
 
TABLE 2: STUDIES DEPICTING ETHNIC DIFFERENCE IN 
CHOROIDAL THICKNESS
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thicker in the morning.(62)
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CHOROIDAL THICKNESS IN VARIOUS DISEASES : 
HIGH MYOPIA:  
 Choroid thickness decreases with increase in axial length. Flores-
Moreno et al. had reported a decrease in choroidal thickness by 25.9 ± 2.1 
microns for every additional millimeter in myopia.(63) 
 
CENTRAL SEROUS CHORIORETINOPATHY: 
 Indocyanine green angiography studies have shown increased 
choroidal permeability in Central serous chorioretinopathy (CSCR). 
Increased choroidal thickness has been reported in patients with acute 
central serous chorioretinopathy. Studies have also reported bilateral 
increase in choroidal thickness patients with unilateral 
CSCR.(55,64,65)Markuno et al by measuring the choroidal thickness 
before and after treatment in CSCR reported a decrease in choroidal 
thickness in patients treated with photodynamic therapy while  o 
difference was reported in patients treated with laser photocoagulation. 
(66) 
 
AGE-RELATED MACULAR DEGENERATION (AMD):  
 Age-related macular degeneration is a multifactorial disease where 
the choroidal blood flow may play a role in the pathogenesis of the 
disesase. SD-OCT has improved the understanding and management of 
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AMD. Manjunath et al. reported that eyes with AMD on an average had a 
thinner choroid than that of normalcontrols. Furthermore, eyes with 
exudative AMD had thinner choroids than eyes with nonexudative AMD.  
 
VOGT–KOYANAGI–HARADA (VKH) DISEASE: 
 Like central seous retinopathy, choroidal hyperpermeability is 
shown to be the main factor in the development of VKH. Studies have 
shown the increase in choroidal thickness in acute stages of VKH. 
Choroidal thickness is reported to decrease with treatment and increase 
with recurrence.  
 
DIABETIC RETINOPATHY: 
 However several studies have reported conflicting results of 
choroidal thickness in diabetic retinopathy. . A large population-based 
study from China reported choroidal thickening in diabetic patients, 
however, diabetic retinopathy did not appear to associate with increased 
choroidal thickness.(67) A recent retrospective study from Korea, 
demonstrated increasing choroidal thickness with increasing severity of 
retinopathy.(52) These conflicting reports may reflect dynamic nature of 
natural history of diabetes and its effect on the eye. 
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REVIEW OF LITERATURE 
 
1. Hayreh et al in 1986 based on his studies on rhesus monkeys first 
reported the morphological and physiological changes in 
hypertensive choroidopathy. Experimental accelerated 
hypertension was produced by modified Glodblatt procedures in 60 
rhesus monkeys. The changes were studied using serial 
ophthalmoscopy and fundus fluorescein angiography in all 
monkeys on a long-term followup.Pathological examination was 
done in 30 eyes. The most common clinical presentations of 
hypertensive choroidopathy were RPE abnormalities and serous 
retinal detachment.Histopathological and angiographic studies 
revealed impaired choroidal circulation with extensive ischemic 
and occlusive changes .These studies revealed that hypertensive 
choroidopathy and retinopathy are two unrelated and independent 
manifestations of accelerated hypertension. (20) 
 
2. Kur et al reported that “ The ability of the retinal vasculature to 
regulate its blood flow is contrasted with the far more restricted 
ability of the choroidal circulation to regulate its blood flow by 
virtue of the absence of glial cells, the markedly reduced 
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pericyteensheathment of the choroidal vasculature, and the lack of 
intermediate filaments in choroidal pericytes”. The authors  
reviewed the cellualar and physiological responses responsible for 
the choroidal and retinal blood flow. (68) 
 
3. Yakugaku et al by their work on the blood vessels in 
spontaneously hypertensive rats demonstrated the impairment of 
endothelium derived relaxation in hypertension.This impairment 
was a result of decreased production of nitric oxide and 
endothelium-derived relaxing factor and increased production of 
endothelium-derived contracting factor. This imbalance in the 
vasocactive mediators in hypertension may be due to the increased 
production of superoxide.The structural damage to the endothelium 
was shown by scanning electron microscopy. The authors 
concluded that in chronic hypertension there is impairment of 
endothelium-dependent relaxation which can be prevented by early 
initiation of anti-hypertensive treatment.(69) 
 
4. Head GA et al reported the increase of several vasoactive 
mediators and also the role of sympathetic system in chronic 
essential hypertension by ganglionic blockade alone and coupled 
with low-frequency oscillations of systolic blood pressure.(21) 
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5. Lütjen-Drecoll et al in 2006 reported the mechanosensory 
properties of the choroidal gaglion cells.He also reported that these 
cells stain positive for several vasomotor mediators like Nitric 
oxide synthetase and Vasoactive intestinal peptide. 
Immunohistochemical staining of choroidal mounts of 21 donor 
eyes was done. Microscopy revealed the presence of a contractile 
smooth muscle unit in the choroid.(70) 
 
6. Chou et al in 2001 demonstrated the presence of choroidal vessel 
denervation super senstivity thus demonstrating the effect of 
circulating catecholamines on choroidal blood vessels. The study 
was conducted in 24 albino rats divided into two groups. 12 rabbits 
received bilateral superior cervical sympathectomy while twelve 
rabbits served as controls.  Four different concentrations of 0.1 ml 
phenylephrine, 0.05%, 0.025%, 0.013%, and 0.007% were slowly 
injected into the vitreous body near the retina. The choroidal blood 
flow was measured simultaneously by laser Doppler flowmetry  
Velocity decreased similarly in both group rabbits except for the 
0.007% phenylephrine, concentration in which velocity decreased 
significantly in group containing the sympathized rabbits. This 
study emphasized the choroidal denervation supersentivity thus 
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demonstrating the effect of catecholamines on choroidal 
vasculature.  
7. Sugiyama et al reported a decrease in peripapillary choroidal 
circulation in normal–tension glaucoma. They also found that a 
decrease in blood pressure was related to reduced blood flow in the 
choroid. 16 patients with normal-tension glaucoma underwent 
computerized image analysis and fluorescein angiography. These 
measurements were correlted with visual fields, retinal vessel 
width, optic disc pallor and blood pressure. (71) 
 
8. Polak et al in 2007 reported the response of the choroidal 
vasculatue to systemic nitric oxide.(72)This was an in-vivo study 
in 16 patients with glaucoma whose were compared to 16 age-
matched controls. All patients underwent subfoveal choroidal flow, 
ocular fundus pulsation amplitude and optic nerve head blood flow 
measurement at baseline and after inhibition of nitric oxide 
synthase by intravenous administration of NG-monomethyl-L-. A 
decrese in choroidal blood flow was seen with inhibition of nitric 
oxide syntetase.  
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9. Leitgeb et al first reported the superiority of the Fourier Domain 
Optical Coherence Tomography systems. They compared it with 
the standard time-domain OCT systems using a charge coupled 
device camera. They reported the larger sensitivity of the Fourier-
Domain OCT systems even in low light with faster detection rates. 
 
10. Ron Margolis et al in 2009 reported his pioneering work on 
Enhanced Depth Imaging Optical Coherence tomography enabling 
choroidal imaging. (60): “The images were obtained by positioning 
the SD OCT device close enough to the eye to obtain an inverted 
representation of the fundus in healthy volunteers who did not have 
pupillary dilation. Seven sections, each comprised of 100 averaged 
scans, were obtained within a 5- x 15-degree rectangle centered on 
the fovea. The choroidal thickness could be evaluated in every 
subject's choroidal image. The mean choroidal thickness under the 
fovea was 318 microm in the right eye and 335 microm in the left 
eye. The choroidal thickness showed a high correlation in both 
eyes The correlation between the measurements performed by the 
independent observers was highly significant. This method 
provides detailed, measurable images from the choroid, a structure 
that heretofore has been difficult to image in clinical practice.” 
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11. Masís et al. studied 112 patients with systemic hypertension and 
15 healthy controls. The mean ages of the two groups were 67 and 
51 years, respectively. The choroidal thickness was significantly 
thinner in hypertensive patients compared to controls.  
 
12. V. Mustafa et al studied a total of 228 eyes of 116 patients with 
essential hypertension and compared them with age-matched 
controls. 89 patients underwent ambulatory blood pressure 
monitoring. These patients were divided into two groups 
depending upon the mean fall of systolic and diastolic pressure at 
night. Those in whom the mean systolic and diastolic blood 
pressures fell by at least 10% at night (compared to day) were 
“dippers,” and the others “nondippers.” All patients underwent 
standard trans thoracic echocardiography and the aortic wall 
distensibility was measured. The authors reported no significant 
difference in sub-foveal choroidal thickness between the test and 
the control group and also between the sub-groups. (73) 
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AIM AND OBJECTIVE 
 
AIM 
 
To measure and compare macular and peripapillay choroidal 
thickness between patients with essential systemic hypertension and 
normal control participants. 
 
OBJECTIVE  
 
To measure and compare macular and peripapillay choroidal 
thickness between patients with essential systemic hypertension and 
normal control participants and to correlate the choroidal thickness in 
hypertensive patients with age, grade of hypertension and hypertensive 
retinopathy. 
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MATERIALS AND METHODS 
 
This was a case–control, cross-sectional prospective study. This 
study was conducted with the approval of our Local Ethics Committee 
and in accordance with the tenets of the Declaration of Helsinki. A total 
of 25 (46 eyes ) patients with systemic hypertension, and 25 ( 46 eyes ) 
healthy controls over 30 years of age, were included. 4 eyes of 2 patients 
in each group were excluded due to the poor image quality .Two eyes of 
2 patients in the hypertension group were excluded due to branch vein 
occlusion while two eyes of two patients in the control group were 
excluded due to prior history of IOL implantation in the past 6 months. 
Illustrated consent forms were given to all participants and were 
explained and signed. Comprehensive ophthalmic examinations were 
performed on all groups. All study participants had best corrected visual 
acuities of 20/25 or more, a refractive error in the range +3.0 to –3.0 
diopters and intraocular pressure (IOP) lower than 21 mmHg. Those with 
systemic or ocular disease (glaucoma, uveitis, high myopia, age-related 
macular degeneration, diabetes mellitus, etc.) or a history of ophthalmic 
surgery that may have affected the choroidal vascular network were 
excluded. All participants in the patient group included in the study were 
hypertensive patients receiving medical treatment and newly diagnosed 
hypertensive patients and with cardiology follow-up. All these patients 
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were diagnosed according to the criterias of the seventh report of the 
Joint Committee on the diagnosis, evaluation and management of 
hypertension (JNC 7). All hypertensive patients were graded into three 
stages based on the World Health Organization guidelines on systemic 
hypertension. All participants were subjected to a thorough medical 
workup and fasting blood sugar, serum cholesterol, blood urea and 
creatinine were done in both groups of participants to rule out secondary 
hypertension, diabetes and hypercholesterolemia. 
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INCLUSION CRITERIA EXCLUSION CRITERIA 
AGE between 30 - 85 years Age <30 or > 85 
Systemic hypertension (under 
treatment) 
Any retinal/ macular diseases 
(Except Grades 1- 3 hypertensive 
retinopathy) H/O ocular 
inflammation/ intraocular surgery 
(except cataract surgery with 
intact posterior capsule before 6 
months from the date of 
enrollment in the study)/ 
intraocular procedure including 
YAG capsulotomy 
Newly diagnosed hypertension 
BP systolic > 140 
      Diastolic > 90 
  Or > 140/90 
BCVA < 6/9 
IOP < 11 or > 20  
REFRACTIVE ERROR < +  
or - 3D 
 Any H/O systemic illness other 
than essential hypertension. 
H/O of smoking 
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INSTRUMENTATION 
 All choroidal thickness measurements were done using the 
SPECTRALIS HRA + OCT platform (Heidelberg Engineering Inc., 
Heidelberg, Germany). All patients also underwent Autofluorescence and 
fundus photography 
 
SPECIFICATIONS: 
Scanning Laser 
Specifications 
(30°/ 20°/ 15°) 
Transversal field of view  
Scan angle: 30°x30°, 20°x20°, 15°x15°  
Wide field composite image to 120°  
High resolution mode Digital image size: 1536x1536 / 
1024x1024 / 768x768.  
Lateral resolution 5 µm/pixel digital Image 
Acquisition Frequency 5 Hz / 7 Hz / 9 Hz Maximum 
Scan Depth 8 mm 
OCT Scanner 
Specifications 
 
A-Scans Scan rate: 40 kHz; Scan depth: 1.8 mm  
Scan size: 512 pixels;Axial resolution: 7 µm optical  
B-Scans Scan angle: 30 / 15 / 10 degrees  
Scan width: up to 9 mm  
High resolution mode Scan width: 1,536 A-Scans  
IMAGING PROTOCOL
The same clinician performed EDI
the morning (between 9 am and 12 pm) with Heidelberg Spectralis 
equipment (Heidelberg Engineering Inc,
FOR MACULAR CHOROIDAL THICKNESS MEASUREMENT:
 
Scan Angle: 30°X15° 
 
Sections : 19 
 
ART: 100 
 
Mode: Enhanced-Depth imaging
 
HIGH-RESOLUTION MODE
 
 
FIG 15: PROTOCOL FOR MACULAR CHOROIDAL 
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-OCT imaging of all subjects in 
 Heidelberg, Germany) . 
 
 
 
THICKNESS 
 
IMAGING PROTOCOL FOR PERIPAPILLARY 
THICKNESS MEASUREMNT:
 
Scan Area: 3.4 mm peripapillary circle centered on the disc
 
ART: 100 scans/second 
 
Mode: Enhanced-Depth imaging
 
HIGH-RESOLUTION MODE
 
 
 
 
 
 
FIG 16: PROTOCOL FOR PERIPAPILLARY CHOROIDAL 
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CHOROIDAL 
 
 
 
 
THICKNESS 
 
CHOROIDAL THICKNESS 
 
The chorioscleral interface is identified. T
the choroid in each image was defined as the hyper
corresponding to the RPE
boundary was defined 
interface. All OCT images were classified and measured by two masked 
trained retinal physicians. After manual delineation of the boundaries, the 
choroidal thickness was measured using the caliper tool available in the 
Spectralis platform. 
FIG 17: OCT IMAGE DEPICTING THE MANUAL 
MEASUREMENT OF THE CHOROIDAL THICKNESS AFTER 
DELINEATING THE ANTERIOR AND POSTERIOR 
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MEASUREMENT: 
he anterior boundary of 
-reflective band 
-Bruch's membrane complex. The posterior 
as the outer boundary of the chorioscleral 
 
BOUNDARIES 
MACULAR CHOROIDAL THICKNESS MEASUREMENT:
 The choroidal thickness was measured at the subfoveal region and 
at 1500 microns nasal, temporal, superior and inferior to the centre of the 
fovea. The centre of the fovea was identified as the region of maximum 
depression. 
FIG 18:  SUB-FOVEAL, NASAL AND TEMPORAL MACULAR 
CHOROIDAL THICKNESS
 
FIG 19: SUPERIOR AND INFERIOR 
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MACULAR CHOROIDAL 
THICKNESS 
 
 
PERIPAPILLARY CHOROIDAL THICKNESS MEASUREMENT:
 The choroidal thickness was measured at the edge of the 3.4 mm 
peripapillary circle at the nasal, temporal, superior and inferior quadrants 
by drawing perpendicular lines from 
caliper tool. 
 
 
 
 
CHORIOSCLERAL INTERFACE GRADING:
All OCT images were graded into four categories based on the 
visibility of the chorioscleral interface along the entire length of the scan. 
OCT images with signal strength less than 6 dB and CSI grade less than 
one were excluded from the study.
 
 
 
FIG 20: OCT IMAGE SHOWING THE MEASUREMENT OF 
CHOROIDAL THICKNESS IN ALL FOUR QUADRANTS
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the centre of the disc using the 
 
 
 
 
CHORIOSCLERAL INTERFACE GRADING:
 
 
 
 
 
 
OCT
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 CSI GRADE
 
1- < 25 % of CSI 
visible 
 
2- 25-50% of CSI 
visible 
 
3- 50-75 % of CSI 
visible 
 
4- > 75% of CSI 
visible 
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STATISTICAL ANALYSIS 
 Mean (SD) or Frequency (Percentage) was used to describe 
summary information.  Student’s t-test was used to assess the difference 
of continuous variable.  Chi-square test or Fisher’s exact test was used to 
assess the association between categorical variables.  P-value is less than 
0.05 considered as statistically significant.  All statistical analysis was 
done by STATA 11.1 (Texas, USA). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
DEMOGRAPHICS:
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Normal
(n=25patient
Age 
Mean(SD) 
  Min - Max 
 
47.24(8.28)
33 - 67
Gender 
Male 
 Female 
 
12(48.0)
13(52.0)
AGE
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RESULTS 
 
 
) 
Hypertension 
(n=25patient) 
Total p-
 
 
 
54.4(9.71) 
37 - 76 
 
50.82(9.63) 
33 – 76  
0.007
 
 
 
15(60.0) 
10(40.0) 
 
27(54.0) 
23(46.0) 
0.72
47.24
54.4
MEAN AGE
CONTROL HYPERTENSIVE
value 
 
† 
 
†† 
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CHOROIOSCLERAL INTERFACE GRADING: 
 
 
 
 
 
 
 
Macular 
CSI grade 
Normal 
(n=44 eyes) 
HTN 
(n=44 eyes) 
Total 
(n=88) 
2 7(15.9) 19(43.2) 26(29.5) 
3 14(31.8) 15(34.1) 29(33.0) 
4 23(52.3) 10(22.7) 33(37.5) 
Perpapillary 
CSI grade 
Normal 
(n=42 eyes) 
HTN 
(n=41 eyes) 
Total 
(n=83) 
2 2(4.8) 2(4.9) 4(4.8) 
3 4(9.5) 13(31.7) 17(20.5) 
4 36(85.7) 26(63.4) 62(74.7) 
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INTEROBSERVER VARIATION: 
 
 
 
 
Inter Observer 
Variability 
HTN Normal 
RE LE RE LE 
Macular Choroid 
Thickness 
    Superior 
    Inferior 
    Nasal 
    Temporal 
       Average 
    Mean 
difference(p-value) 
 
0.485 
0.112 
0.241 
0.400 
 
2.02(0.078) 
 
0.951 
0.217 
0.754 
0.368 
 
5.92(0.298) 
 
0.666 
0.333 
0.379 
0.407 
 
0.93(0.076) 
 
0.262 
0.186 
0.221 
0.232 
 
0.98(0.324) 
Peripapillary 
Choroid Thickness 
    Superior 
    Inferior 
    Nasal 
    Temporal 
Average 
    Mean 
difference(p-value) 
 
0.857 
0.633 
0.127 
0.196 
 
1.14(0.257) 
 
0.256 
0.019 
0.346 
0.906 
 
4.16(0.180) 
 
0.599 
0.656 
0.275 
0.068 
 
0.18(0.782) 
 
0.187 
0.343 
0.782 
0.283 
 
0.52(0.374) 
SUBFOVEAL CHOROIDAL THICKNESS:
The mean subfoveal thickness was significantly thicker in the 
hypertensive group. 
Subfoveal 
Choroid 
Thickness 
Normal
 
Sub foveal  
Mean(SD) 
 Min – Max 
 
 
311.31(68.15)
207.0 – 476.5
 
 
 
 
 
 
 
SUB-FOVEAL CHOROIDAL THICKNESS
SUBFOVEAL CHOROIDAL THICKNESS
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Hypertension 
 
Total 
 
 
 
 
347.92(71.89) 
195 – 491.5 
 
 
329.11(71.99)
195 – 491.5 
311.31
HYPERTENSION CONTROL
 
p-value 
 
 
 
0.015 
347.92
MACULAR CHOROIDAL THICKNESS:
 
         
Macular 
Choroid 
Thickness 
Normal
Superior 
Mean(SD) 
    Min - Max 
282.57(64.04)
168.5 
Inferior 
Mean(SD) 
    Min - Max 
276.53(70.30)
153.5 
Nasal 
Mean(SD) 
    Min - Max 
274.54(71.87)
147.0 
Temporal 
Mean(SD) 
    Min - Max 
258.26(70.69)
147.0 
SUPERIOR
INFERIOR
NASAL
TEMPORAL
MACULAR CHOROIDAL THICKNESS
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 Hypertension Total 
 
 
– 406.0 
 
322.01(62.41) 
172.0 – 432.0 
 
303.81(65.80)
168.5 – 432.0
 
 
– 418.5 
 
315.46(66.23) 
184.0 – 471.5 
 
297.49(70.45)
153.5 – 471.5
 
 
– 456.5 
 
303.17(73.92) 
156.0 – 440.0 
 
288.70(73.89)
147.0 – 456.5
 
 
– 432 
 
319.09(80.37) 
140.0 – 494.5 
 
288.33(81.18)
140.0 – 494.5
282.57
276.53
274.54
258.26
HYPERTENSIVE CONTROL
p-value 
 
 
0.008 
 
 
0.014 
 
 
0.067 
 
 
0.0003 
322.01
315.46
303.17
319.09
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The subfoveal and the macular choroidal thickness 1500 microns 
superior, inferior and temporal to the center of the fovea was significantly 
thicker in the hypertension group compared to normal individuals. The 
sub-foveal choroidal thickness was the highest followed by the temporal 
macular choroidal thickness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PERIPAPILLARY CHOROIDAL THICKNESS
 
 
 Normal
Superior 
Mean(SD) 
 Min - Max 
 
187.87(46.69)
87.5 – 268.5
Inferior 
Mean(SD) 
 Min - Max 
 
139.25(38.99)
62.0 – 202.5
Nasal 
Mean(SD) 
Min - Max 
 
175.79(60.53)
78.0 – 325.5
Temporal 
Mean(SD) 
 Min - Max 
 
198.64(61.48)
87.0 – 317.5
SUPERIOR
INFERIOR
NASAL
TEMPORAL
PERIPAPILLARY CHOROIDAL THICKNESS
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: 
 Hypertension Total 
 
 
 
217.01(65.96) 
87.5 – 357.5 
 
202.26(58.54) 
87.5 – 357.5 
 
 
 
162.51(56.81) 
62.5 – 290.0 
 
150.74(49.71) 
62.0 – 290.0 
 
 
 
186.04(61.61) 
50.5 – 293.0 
 
180.85(60.91) 
50.5 – 325.5 
 
 
 
238.64(72.05) 
58.5 – 379.5 
 
218.40(69.48) 
58.5 – 379.5 
187.87
139.25
175.79
198.64
217.01
162.51
186.04
238.64
HYPERTENSIVE CONTROL
p-value 
0.023 
0.033 
0.447 
0.008 
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Like the macular choroidal thickness, the peripapillary choroidal 
thickness was significantly thicker in the hypertensive group compared to 
the normal participants. The peripapillary choroidal thickness was 
thinnest in the inferior quadrant and thickest in the temporal quadrant. 
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SUB-FOVEAL CHOROIDAL THICKNESS AND AGE: 
 
 
 
 
Variable 
Regression coefficient 
(95% CI) 
P-value 
Normal 
<=40 
      41 – 50  
      51 – 60  
>60 
 
- 
-31.88(-84.10, 20.33) 
-60.42(-121.44, 0.61) 
-83.67(-163.48, -3.86) 
 
- 
0.225 
0.052 
0.040 
Hypertension 
<=40 
      41 – 50  
      51 – 60  
>60 
 
- 
79.18(-30.61, 188.97) 
48.43(-57.50, 154.35) 
22.45(-87.34, 132.24) 
 
- 
0.153 
0.361 
0.382 
Hypertension
Normal
2
0
0
3
0
0
4
0
0
5
0
0
S
u
b
fo
ve
a
l m
a
cu
la
r 
th
ic
kn
e
ss
30 40 50 60 70 80
Age
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DISCUSSION 
The choroid is a highly vascular tissue. The choroid has one of the 
highest blood flow probably the highest in terms of per unit tissue.  The 
choroidal blood flow in terms of per unit tissue is almost ten times of that 
of the brain.(37) The choroidal circulation provides major supply of 
nutrients and oxygen to the outer retina especially the photoreceptos. 
Unlike the retinal circulation, autoregulation in the choroidal circulation 
is believed to be limited. The choroid is largely under the control of the 
autonomic nervous system.(70) The role of the choroid in the 
pathophysiology of several diseases including age-related macular 
degeneration, Vogt-Koyanagi Harada disease and central serous 
retinopathy has been proved.(65,74,75) Hypertension is the third most 
common risk factor for non-communicable diseases in South Asia and 
about thirty percent of Indians are hypertensive patients.(5) Considering 
the high vascularity of the choroid, the changes induced by hypertension 
on the choroid has been studied sparsely. This may be largely because of 
the inaccessibility of the choroidal tissue for in vivo investigations in the 
past. Postmortem examinations of the choroid have been proven to have 
little clinical value .Postmortem fixation and absence of circulation in 
postmortem samples may not provide accurate data for correlation with in 
vivo mechanisms. However with the advent of Enhanced depth imaging 
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Optical Coherence Tomography , the till now inaccessible choroid is 
made available for extensive research. (13) The choroidal tissue is also 
made up of several unique anatomical features .The choroid consists of 
intrinsic choroidal neurons which are largely responsible for the 
vasomotor control of the choroid.(68) The choroid also consists on non-
vascular smooth muscle tissue which are arranged as a single layer 
parallel to the bruch membrane. Several vasoactive mediators such as 
endothelin-1 and catecholamines have been proven to increase in the 
blood of patients with hypertension.(21,76) The large fenestrations of the 
choriocapillaries have cause easy transduation of these mediators 
resulting in morphological and physiological changes to the choroidal 
tissue. The morphological and physiological changes in the choroid to 
accelerated malignant hypertension has been extensively studied. Hayreh 
was the first to perform extensive research on this subject. Following his 
study on sixty rhesus monkeys with malignant hypertension produced by 
Goldbatt technique, Hayreh was the first to recognize hypertensive 
choroidopathy as an independent and important clinical entity different 
from hypertensive retinopathy. (20) The choroid has been proven to be a 
highly dynamic structure capable of modulating its thickness. The 
choroidal thickness has been reported to vary with several factors 
including age, axial length and ethnicity. (77) The age-related choroidal 
thinning has been also shown in several postmortem studies. OCT studies 
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have also demonstrated a gradual decline in choroidal thickness with 
age.(55,61) This decline in choroidal thickness with age is usually greater 
after the sixth decade.(78) Though the choroid has been reported to 
increase in thickness in acute hypertension, the pathophysiology of 
malignant hypertension is totally different from that of chronic systemic 
hypertension. The choroidal vasculature changes in chronic hypertension 
was reported by Imran Bhutto in spontaneously hypertensive rats.(79) 
Scanning electron microscopy of the choroid in the hypertensive rats 
revealed a decrease in the number of choroidal arteries and venules 
.Transmission electron microscopy studies revealed hypertrophy of the 
smooth vessels of the vascular wall. M Gok et al reported no change in 
the choroidal thickness between hypertensive and normal patients. (80) 
However, the increase in the choroidal thickness in hypertensive patients 
can be explained by several theories. The choroidal thickness has been 
shown to change both as a transient and permanent response to several 
stimuli. Transient changes in choroidal thickness have been reported in 
chick embryos to myopic and hyperopic defocus. (81) Though several 
mechanism for this transient change in choroidal thickness have been 
proposed, the most accepted is the filling up of the large lacunae present 
in the choroidal stroma. This happens because of the contraction of the 
choroidal nonvascular smooth muscle. These smooth muscles are 
arranged parallel and not perpendicular to the choroidal tissue thus 
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causing filling up of the lacunae in response to the constriction. The 
smooth muscle hypertrophy is one of the most consistent reported 
morphological changes in chronic hypertension.(82) Thus chronic 
hypertension may cause choroidal vascular smooth muscle contraction 
resulting in an increase in the choroidal thickness. The permanent 
increase in choroidal thickness as a response to prolonged refractive 
defocus has been reported in several studies thus highlighting the role of 
the choroid in emmetropization. These studies report the ability of the 
choroid in secreting several growth factors such as transforming growth 
factor, fibroblast growth factor and several other mediators affecting 
smooth muscle proliferation and vasomotor tone.(77) Schindler et al 
reported an augmentation of growth factors in chronic hypertension. (83) 
The increased expression of growth factors in chronic hypertension and 
the intrinsic ability of the choroid to secrete growth factors may also 
cause morphological changes in the choroidal tissue thus explaining the 
increase in choroidal thickness in hypertensive patients. 
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LIMITATIONS 
 Small sample size 
 There was a significant difference in the mean age of the control 
group and the hypertensive patients, which may have played a 
confounding role in the choroidal thickness measurements. 
 Water and caffeine intake were not regulated in our participants and 
these are reported to influence choroidal thickness. 
 The chorioscleral interface grading was done considering the visibility 
of the interface along the length of the entire scan. The visibility of 
this interface at the sub-foveal region was not included in the criteria 
for the grading. 
 The image quality of the OCT images in the hypertensive group was 
less than the control group, which could have hampered accurate 
measurement of the choroidal thickness. 
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CONCLUSION 
 The advent of newer Optical Coherence Tomography systems like 
the Enhanced Depth Imaging technology has made the previously 
inaccessible choroid available for in-vivo imaging in several disease 
states. The role of essential hypertension as a co morbid factor in several 
retinal and choroidal diseases is still largely unclear. Several population 
studies and hospital based studies are required for better understanding of 
the choroid and the role elevated blood pressure plays in the 
pathophysiology of glaucoma and several retinal diseases. 
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PROFORMA 
 
 
 
NAME:                                                                       DATE: 
 
STUDY NO:                                                              MR NO: 
 
AGE: 
 
GENDER:  
 
 
BLOOD PRESSURE: (2 MEASUREMENTS FOR HYPERTENSIVES) 
 
 SYSTOLIC DIASTOLIC TIME 
1ST 
MEASUREMENT 
   
2ND 
MEASUREMENT 
   
 
 
 
 
BLOOD INVESTIGATIONS: 
 
Fasting blood sugar: 
 
Blood urea: 
 
Serum creatinine: 
 
Total cholesterol: 
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STUDY EYE: RE/LE/BE 
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REFRACTION 
  
SPHERICAL 
EQUIVALENT 
  
ANTERIOR 
SEGMENT 
  
IOP 
 
  
FUNDUS   
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MACULAR   
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MACULAR CHOROIDAL THICKNSS 
 RE LE 
    
SUBFOVEAL     
SUPERIOR     
INFERIOR     
NASAL     
TEMPORAL     
PERIPAPILLARY CHOROIDAL THICKNSS 
 RE LE 
    
SUPERIOR     
INFERIOR     
NASAL     
TEMPORAL     
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 
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RE LE OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2
1 1976238 PREMALATHA 50 F RE 0.35 279 281 253 245 256 260 240 238 221 230
2 840830 GANESAN 45 M BE 0 0 413 400 386 380 382 375 340 342 220 230 289 287 300 310 300 310 345 343 289 288
3 1976231 DHANBAK 53 F BE 1.25 0.75 338 335 275 273 261 270 240 235 284 280 230 224 245 242 236 239 250 244 256 259
4 1683059 PALANISAMY 47 M BE -0.35 0 242 245 240 235 230 234 163 165 217 220 235 223 170 166 157 160 230 223 232 222
5 1977982 rengaraj 44 M RE 0.25 284 291 232 234 186 190 294 290 281 275
6 1977917 SHABEER ALI 34 M BE -1.25 -0.75 430 433 420 425 374 377 395 399 385 376 191 198 416 421 369 372 372 377 343 341
7 1977943 CHANDRASEKAR 44 M BE 0.25 0.25 374 380 289 295 320 315 295 290 341 347 268 271 307 310 302 305 268 275 273 275
8 1977927 RAJAGOPALAN 61 M BE 0.3 0.3 253 245 240 244 176 170 191 195 145 150 179 174 240 243 196 200 222 225 258 253
9 1977919 SARASWATHI 52 F BE 1 1.25 343 333 233 225 281 283 408 400 258 266 219 224 310 304 344 345 245 255 366 369
10 1978719 CHANDRASEKAR S 43 M BE 0.25 0.25 235 240 273 275 145 149 204 208 217 220 207 210 222 225 222 223 190 198 207 208
11 1436019 LOGAMBAL 41 F BE 0 0 336 330 460 459 382 274 399 394 382 384 400 395
12 1980374 S BABY 40 F BE 0 0 269 272 292 288 235 240 226 230 331 335 248 244
13 1980340 KANAMMAL 48 F BE -2 -0.75 325 328 263 256 311 301 274 277 238 242 199 190
14 1980342 SHANMUGAM 67 M BE 0 0 292 295 274 269 285 289 250 245 274 270 173 180
15 1980359 CHINNAPONNU 45 F BE 0.75 0 276 277 279 281 176 180 274 270 178 180 200 199
16 1981179 chandrika 60 F BE 2 2 281 282 240 232 302 298 279 281 289 294 222 226 227 230 237 230 295 290 222 219
17 1981192 AMUTHA 48 F BE 1.25 1.25 356 352 348 351 315 318 281 285 260 305 300 331 335 333 331 323 330 330 334
18 1981219 REJINI 40 F BE 0 0 395 398 426 417 301 296 341 345 264 270 346 341 377 385 346 350 410 402 390 395
19 1981520 SRINIVASAN 50 M LE 0.75 300 305 235 238 250 255 261 265 285 280
20 1984402 NALINI 52 F BE 1.5 1.5 354 350 279 285 274 277 227 231 346 350 287 283 313 316 240 245 271 275 274 274
21 1759415 S K SUDHA 33 F BE -1 -1 357 361 328 333 314 320 348 345 348 345 294 300 343 339 387 385 395 390 284 287
22 1981594  BALAKRISHNAN 42 M BE 0 0 236 243 232 229 166 170 206 210 214 218 173 175 181 185 152 155 227 230 272 270
23 1984391 SAIDALI 59 M BE 0 0.5 330 319 220 218 233 230 218 210 237 230 150 144 280 284 232 228 200 210 225 220
24 1984424 NALLASAMY 40 M RE 0 0 204 210 192 200 160 155 180 177 172 165
25 1984413 NIRMALADEVI 43 F BE 0.5 0 354 360 483 470 235 230 462 451 320 329 434 430 261 257 382 377 364 357 390 380
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 MACULAR CHOROIDAL THICKNESS (micrometer )
SUBFOVEAL NASAL TEMPORAL INFERIOR
OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 RE LE RE LE
114 117 227 220 140 147 240 246 2 3
253 245 225 230 315 320 292 284 196 190 147 150 205 210 204 210 2 3 4 4
155 150 136 137 176 180 188 190 145 140 158 152 230 224 176 170 3 3 4 4
106 110 77 79 111 120 85 90 60 64 77 75 85 90 121 115 4 4 4 4
264 257 294 286 155 160 269 264 3 4
176 180 209 205 310 319 292 296 168 177 145 142 194 199 261 267 2 2 3 4
119 121 121 122 214 222 212 221 137 135 124 120 178 182 153 157 3 4 4 4
106 105 168 165 119 123 147 150 83 80 90 88 111 115 161 165 2 3 4 4
209 214 255 250 294 290 300 310 199 190 188 180 238 233 244 250 2 2 2 2
4 4
93 89 114 110 88 86 122 124 80 78 96 98 132 131 109 115 4 4 4 4
201 204 199 201 222 224 203 206 191 183 190 185 204 210 230 228 4 4 4 4
140 145 106 100 170 176 159 155 98 100 88 92 184 180 114 122 3 3 3 3
103 105 145 150 145 150 180 175 100 101 130 120 230 225 197 202 3 3 4 4
266 260 215 213 232 235 212 220 126 130 109 112 271 266 214 219 4 4 4 4
186 180 191 188 189 188 201 205 200 192 160 162 217 215 204 200 4 4 4 4
194 196 150 155 222 225 227 225 150 155 174 170 186 188 186 189 4 3 4 4
116 119 186 180 122 120 194 191 4 4
183 189 171 175 217 222 201 205 170 169 155 160 160 158 176 180 3 4 4 4
168 162 250 251 142 145 279 274 139 133 200 205 145 150 266 260 4 4 4 4
176 170 266 260 127 130 173 175 90 92 98 100 145 142 205 210 4 4 4 4
333 318 305 310 204 210 183 190 194 190 152 160 204 210 178 185 3 3 4 4
142 140 121 118 120 129 111 118 4 4
121 122 168 172 150 145 176 170 134 128 188 177 155 150 181 172 4 4 4 4
RE LERE LE RE LE RE LE
NASAL TEMPORAL INFERIOR SUPERIOR
CSI GRADING
MACUAR PERIPAPILLARY
PERIPAPILLARY CHOROIDAL THICKNESS (micrometer )
RE LE OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2
1613928 durairaj 1 LE 74 m 0 0 3 0 0 232 235 195 198 272 273 219 222 222 226 147 150 89 92
1969211 RANGARAJ 2 BE 58 M 0.25 O.50 10 0 0 326 333 336 339 335 343 279 285 320 312 295 300 372 363 357 363 320 311 269 674 289 291 243 247 140 145 170 167
1628093 chandar 3 BE 52 M -2 -2 10 0 1 490 493 460 463 337 380 330 332 501 488 485 470 372 379 434 430 433 438 377 379 279 283 192 195 243 247 140 145
1969914 rajani 4 BE 41 F 0 0 3 1 0 379 375 360 352 325 315 310 320 351 342 340 332 270 280 292 270 333 320 310 300 338 330 353 362 266 259 265 269
1976221 ANTHONY CRUZ 5 BE 63 M 1 1.25 2 2 1 291 287 315 320 240 232 305 310 256 262 328 320 380 372 370 377 227 225 358 364 217 209 248 250 140 136 119 128
1969948 SAVITHRI 6 BE 54 F 0 0 10 0 2 460 449 475 460 400 421 411 390 430 421 426 418 399 385 420 411 415 405 431 450 276 270 248 241 199 195 190 199
1788636 PERIYASAMY 7 RE 76 M 0  10 1 2 315 320 300 290 343 338 305 310 346 349 140 141 90 95
1969221 RAJESHWARI 8 BE 49 F -0.25 -0.5 3 0 0 330 339 364 360 248 253 261 270 263 270 328 334 294 300 305 310 310 316 370 362 160 165 199 190 145 138 156 150
1970083 SAROJINI 9 BE 51 F 1.5 1 6 0 0 240 237 227 220 163 167 180 185 261 269 212 220 384 390 274 280 292 299 250 260 150 141 165 160 75 80 91 99
1969325 REGIYA 10 BE 37 F -1.5 -1.5 5 2 1 292 300 302 308 232 227 245 250 277 280 225 237 366 377 314 330 372 370 323 338 143 150 204 410 121 130 124 129
1969475 PRADEEP 11 LE 51 M 0 0 1 2 454 440 382 370 440 421 405 390 304 320 290 275 147 140
1938021 mohammed 12 RE 61 M 0 4 1 2 190 200 177 185 142 150 175 180 180 188
1719752 CHANDRAN 13 BE 60 M 0 0 3 1 0 336 330 292 283 261 255 269 260 310 300 400 407 325 329 392 400 369 360 410 399
1976815 MURUGAN 14 BE 41 M -0.3 -0.3 0 2 1 351 340 330 333 310 300 222 213 372 368 152 149 395 390 252 259 207 218 328 333 147 155 222 229 169 160 145 152
1336387 SAKTHIVEL 15 RE 43 M 0 0 5 0 0 410 408 346 350 343 337 236 230 245 256 250 246 210 204
1977921 ? 16 BE 44 F 0.5 -0.5 2 0 0 446 421 501 430 421 400 430 405 407 391 462 447 246 250 293 301 292 288 220 229
1977964 USHA NAIR 17 BE 62 F 2.25 2 9 0 0 320 337 336 354 304 297 379 385 290 288 373 370 288 300 340 328 272 290 318 330 225 220 207 210 142 144 121 124
1728873 NAGARAJ 18 BE 64 M 0 0.5 20 1 0 390 388 430 421 361 379 369 385 330 339 376 385 290 301 340 356 300 301 270 277 238 240 263 270 243 250 171 180
1981582 ? 19 BE 61 M 0 0 10 0 0 374 367 338 345 383 388 431 449 243 249 130 150 310 313 280 290 284 295 250 260 225 230 221 229 232 240 205 213
1970147 ? 20 RE 54 M 0 2 1 1 302 310 280 287 292 294 285 287 288 290 127 125 109 112
1987097 sivakumar 21 be 53 m 1.25 1.25 1 0 0 314 320 404 320 280 290 333 339 300 294 308 331 333 311 329 320 254 270 304 318 183 190 190 200 130 134 150 151
1987106 VASANTHAMANI 22 BE 45 F 0.75 0.3 5 0 0 354 345 406 419 256 270 335 350 284 270 364 355 284 279 383 372 348 340 352 341 132 140 204 210 152 155 157 160
1989828 ? 23 BE 54 F 1.5 1.75 2 0 0 341 331 320 312 326 320 315 320 300 309 380 287 330 341 300 304 300 305 272 280 175 177 163 167 122 130 132 138
1392683 MANOHAR 24 BE 57 M 2 1.75 4 1 2 390 410 394 410 328 340 360 350 323 335 369 351 350 352 380 371 299 310 405 415 276 266 333 326 230 225 235 230
1989413 BANUMATHI 25 BE 55 F 1 1.5 3 3 1 243 245 222 226 155 157 183 175 251 248 253 262 170 174 209 215 212 218 230 240 88 90 85 90 83 79 65 60
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 MACULAR CHOROIDAL THICKNESS (micrometer ) PERIPAPILLARY CHOROIDAL THICKNESS (micrometer )
RE LE RE
OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 OBV 1 OBV 2 RE LE RE LE
171 175 85 90 4 4
233 235 232 240 316 321 238 233 3 3 4 4
217 220 213 222 269 275 238 229 3 3 3 4
279 268 275 265 291 283 292 285 2 2 2 3
160 167 229 219 194 196 243 245 4 3 4 4
297 289 225 230 364 360 284 290 2 2 3 3
137 140 199 202 2 4
165 159 260 250 183 178 219 210 4 4 4 4
101 108 111 118 163 167 145 141 4 4 4 4
145 150 137 149 178 184 227 236 2 2 3 3
154 160 294 280 2 2
4
3 3
215 220 235 240 287 294 266 274 3 3 4 4
212 210 269 272 3 4
210 219 200 190 196 188 310 315 2 2 3 3
176 180 227 220 248 253 233 238 2 2 3 3
240 249 201 210 279 287 334 340 3 3 4 4
160 165 134 140 281 288 302 306 3 3 4 4
124 130 201 198 4 4
180 182 190 194 200 210 220 211 2 2 3 3
98 102 170 174 201 211 250 239 2 2 4 4
109 111 100 103 225 220 200 210 3 2 4 4
287 280 281 275 341 333 379 380 2 2 3 4
52 54 49 52 67 69 57 60 4 4 4 4
CSI GRADING
MACULAR
NASAL
RE LE
PERIPAPILLARY CHOROIDAL THICKNESS (micrometer )
TEMPORAL
RE LE PERIPAPILLARY
